$4.02
6.63% yesterday
Nasdaq, Aug 12, 10:02 pm CET
ISIN
US48576U1060
Symbol
KPTI

Karyopharm Therapeutics, Inc. Stock price

$4.02
-0.75 15.72% 1M
-4.77 54.25% 6M
-6.12 60.37% YTD
-8.20 67.11% 1Y
-77.13 95.05% 3Y
-218.73 98.20% 5Y
-190.98 97.94% 10Y
-236.73 98.33% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.25 6.63%
ISIN
US48576U1060
Symbol
KPTI
Industry

Key metrics

Basic
Market capitalization
$32.6m
Enterprise Value
$215.4m
Net debt
$182.9m
Cash
$69.9m
Shares outstanding
8.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.2 | 0.2
EV/Sales
1.5 | 1.5
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-113.1%
Return on Equity
41.1%
ROCE
-198.8%
ROIC
-148.7%
Debt/Equity
-1.2
Financials (TTM | estimate)
Revenue
$142.1m | $148.4m
EBITDA
$-73.9m | $-132.6m
EBIT
$-74.2m | $-110.6m
Net Income
$-62.5m | $-106.5m
Free Cash Flow
$-122.7m
Growth (TTM | estimate)
Revenue
1.2% | 2.2%
EBITDA
44.1% | -11.3%
EBIT
44.0% | 7.4%
Net Income
57.3% | -39.4%
Free Cash Flow
-4.2%
Margin (TTM | estimate)
Gross
96.2%
EBITDA
-52.0% | -89.4%
EBIT
-52.2%
Net
-44.0% | -71.8%
Free Cash Flow
-86.3%
More
EPS
$-7.4
FCF per Share
$-14.3
Short interest
24.1%
Employees
279
Rev per Employee
$520.0k
Show more

Is Karyopharm Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Karyopharm Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Karyopharm Therapeutics, Inc. forecast:

10x Buy
77%
3x Hold
23%

Analyst Opinions

13 Analysts have issued a Karyopharm Therapeutics, Inc. forecast:

Buy
77%
Hold
23%

Financial data from Karyopharm Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
142 142
1% 1%
100%
- Direct Costs 5.40 5.40
2% 2%
4%
137 137
1% 1%
96%
- Selling and Administrative Expenses 113 113
10% 10%
80%
- Research and Development Expense 142 142
0% 0%
100%
-74 -74
44% 44%
-52%
- Depreciation and Amortization 0.33 0.33
0% 0%
0%
EBIT (Operating Income) EBIT -74 -74
44% 44%
-52%
Net Profit -63 -63
57% 57%
-44%

In millions USD.

Don't miss a Thing! We will send you all news about Karyopharm Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Karyopharm Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
one day ago
Karyopharm Therapeutics Inc. (NASDAQ:KPTI ) Q2 2025 Earnings Call August 11, 2025 8:00 AM ET Company Participants Brendan Twohig Strong - Corporate Participant SVP of Investor Relations & Corporate Communications - Corporate Participant Lori A. Macomber - EVP, CFO & Treasurer Reshma Rangwala - Executive VP, Chief Medical Officer & Head of Research Richard A.
Neutral
PRNewsWire
one day ago
– New Patient Screening for Phase 3 SENTRY Trial in Myelofibrosis Expected to Close This Week; Top-Line Results Anticipated in March 2026 – – Total Revenue was $37.9 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was $29.7 Million, up 6% compared to Second Quarter of 2024 – – Reaffirms Full-Year 2025 Total Revenue Guidance of $140 Million to $155 Million; Updates U.S. XPOVIO Net Product ...
Neutral
PRNewsWire
8 days ago
-- Conference Call Scheduled for Monday, August 11, 2025, at 8:00 a.m. ET -- NEWTON, Mass.
More Karyopharm Therapeutics, Inc. News

Company Profile

Karyopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Its SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Head office United States
CEO Richard Paulson
Employees 279
Founded 2008
Website karyopharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today